Biomarkers and Surrogate Endpoints for Normal-tissue Effects of Radiation Therapy: the Importance of Dose-volume Effects

Overview

Journal Int J Radiat Oncol Biol Phys

Specialties Oncology
Radiology

Date 2010 Feb 23

PMID 20171510

Citations 31

Authors

Soren M Bentzen

Matthew Parliament

Joseph O Deasy

Adam Dicker

Walter J Curran

Jacqueline P Williams

Barry S Rosenstein

Affiliations

Soon will be listed here.

Abstract

Biomarkers are of interest for predicting or monitoring normal tissue toxicity of radiation therapy. Advances in molecular radiobiology provide novel leads in the search for normal tissue biomarkers with sufficient sensitivity and specificity to become clinically useful. This article reviews examples of studies of biomarkers as predictive markers, as response markers, or as surrogate endpoints for radiation side effects. Single nucleotide polymorphisms are briefly discussed in the context of candidate gene and genomewide association studies. The importance of adjusting for radiation dose distribution in normal tissue biomarker studies is underlined. Finally, research priorities in this field are identified and discussed.

Citing Articles

Novel model integrating computed tomography-based image markers with genetic markers for discriminating radiation pneumonitis in patients with unresectable stage III non-small cell lung cancer receiving radiotherapy: a retrospective multi-center....

Li J, Li L, Tang S, Yu Q, Liu W, Liu N BMC Cancer. 2024; 24(1):78.

PMID: 38225543 PMC: 10789008. DOI: 10.1186/s12885-023-11809-y.

Cytokine Levels in Saliva Are Associated with Salivary Gland Fibrosis and Hyposalivation in Mice after Fractionated Radiotherapy of the Head and Neck.

Zlygosteva O, Juvkam I, Aass H, Galtung H, Soland T, Malinen E Int J Mol Sci. 2023; 24(20).

PMID: 37894899 PMC: 10607825. DOI: 10.3390/ijms242015218.

Heterogeneity of absorbed dose distribution in kidney tissues and dose-response modelling of nephrotoxicity in radiopharmaceutical therapy with beta-particle emitters: A review.

Vargas C, Andersson M, Bouvier-Capely C, Li W, Madas B, Covens P Z Med Phys. 2023; 34(4):491-509.

PMID: 37031068 PMC: 11624361. DOI: 10.1016/j.zemedi.2023.02.006.

The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review.

Pereira S, Orlandi E, Deneuve S, Barcellini A, Chalaszczyk A, Behm-Ansmant I Cancers (Basel). 2022; 14(24).

PMID: 36551737 PMC: 9776433. DOI: 10.3390/cancers14246252.

Demystifying radiation oncology clinical trial concerns for protocol scientific review and institutional review board committee members.

Qazi J, DeHaai K, Hawkins B, Romano K, Zaorsky N, Chen R Contemp Clin Trials Commun. 2022; 27:100911.

PMID: 35345873 PMC: 8956792. DOI: 10.1016/j.conctc.2022.100911.

References

Safwat A, Bentzen S, Turesson I, Hendry J . Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys. 2002; 52(1):198-204. DOI: 10.1016/s0360-3016(01)02690-6. View

Alsner J, Andreassen C, Overgaard J . Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol. 2008; 18(2):126-35. DOI: 10.1016/j.semradonc.2007.10.004. View

Bentzen S, Overgaard M . Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. Radiother Oncol. 1991; 20(3):159-65. DOI: 10.1016/0167-8140(91)90092-u. View

Evans E, Kocak Z, Zhou S, Kahn D, Huang H, Hollis D . Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer?. Cytokine. 2006; 35(3-4):186-92. PMC: 1829192. DOI: 10.1016/j.cyto.2006.07.021. View

Barnett G, West C, Dunning A, Elliott R, Coles C, Pharoah P . Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer. 2009; 9(2):134-42. PMC: 2670578. DOI: 10.1038/nrc2587. View

MUNRO T, Gilbert C . The relation between tumour lethal doses and the radiosensitivity of tumour cells. Br J Radiol. 1961; 34:246-51. DOI: 10.1259/0007-1285-34-400-246. View

Zhao L, Wang L, Ji W, Wang X, Zhu X, Hayman J . Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan. Int J Radiat Oncol Biol Phys. 2009; 74(5):1385-90. DOI: 10.1016/j.ijrobp.2008.10.065. View

Anscher M, Marks L, Shafman T, Clough R, Huang H, Tisch A . Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 2003; 56(4):988-95. DOI: 10.1016/s0360-3016(03)00184-6. View

Li C, Wilson P, Levine E, Barber J, Stewart A, Kumar S . TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int J Cancer. 1999; 84(2):155-9. DOI: 10.1002/(sici)1097-0215(19990420)84:2<155::aid-ijc11>3.0.co;2-s. View

10.

Cohn J . Introduction to surrogate markers. Circulation. 2004; 109(25 Suppl 1):IV20-1. DOI: 10.1161/01.CIR.0000133441.05780.1d. View

11.

Bentzen S, Thames H, Overgaard M . Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study. Radiother Oncol. 1989; 15(3):267-74. DOI: 10.1016/0167-8140(89)90095-9. View

12.

Le Tourneau C, Lee J, Siu L . Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009; 101(10):708-20. PMC: 2684552. DOI: 10.1093/jnci/djp079. View

13.

Bentzen S, Saunders M, Dische S, Bond S . Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol. 2001; 60(2):123-35. DOI: 10.1016/s0167-8140(01)00358-9. View

14.

Bentzen S, Overgaard M, Overgaard J . Clinical correlations between late normal tissue endpoints after radiotherapy: implications for predictive assays of radiosensitivity. Eur J Cancer. 1993; 29A(10):1373-6. DOI: 10.1016/0959-8049(93)90004-y. View

15.

Okunieff P, Chen Y, Maguire D, Huser A . Molecular markers of radiation-related normal tissue toxicity. Cancer Metastasis Rev. 2008; 27(3):363-74. PMC: 2800946. DOI: 10.1007/s10555-008-9138-7. View

16.

Bentzen S . From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities. Semin Radiat Oncol. 2008; 18(2):75-88. DOI: 10.1016/j.semradonc.2007.10.003. View

17.

Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, Fallone G . Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res. 2006; 12(8):2545-54. DOI: 10.1158/1078-0432.CCR-05-2703. View

18.

Bentzen S, Buffa F, Wilson G . Multiple biomarker tissue microarrays: bioinformatics and practical approaches. Cancer Metastasis Rev. 2008; 27(3):481-94. DOI: 10.1007/s10555-008-9145-8. View

19.

Roses A . Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov. 2002; 1(7):541-9. DOI: 10.1038/nrd840. View

20.

West C, McKay M, Holscher T, Baumann M, Stratford I, Bristow R . Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys. 2005; 62(5):1264-73. DOI: 10.1016/j.ijrobp.2005.05.001. View